Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines

Sophie Cowman^{1,2}, Barry Pizer³ and Violaine Sée^{1*}

Affiliations:

¹ University of Liverpool, Institute of Integrated Biology, Department of Biochemistry; Centre for Cell Imaging, Liverpool, L69 7ZB, UK

² Current address: University of Utah, Department of Pharmacology and Toxicology, College of Pharmacy, Salt Lake City, Utah, 84112, USA

³ Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK

E-mail addresses for all authors:

Sophie Cowman: sophie.cowman@utah.edu

Barry Pizer: Barry.Pizer@alderhey.nhs.uk

*Corresponding author: Violaine Sée: violaine@liverpool.ac.uk

Tel: +44 (0)151 795 4598 or 4454; Fax: +44 (0)151 795 4404

Running title: Global alteration of DNA repair gene expression by hypoxia

Word count: 3996

Abstract

Glioblastoma, a grade IV astrocytoma, has a poor survival rate in part due to ineffective treatment options available. These tumours are heterogeneous with areas of low oxygen levels, termed hypoxic regions. Many intra-cellular signalling pathways, including DNA repair, can be altered by hypoxia. Since DNA damage induction and subsequent activation of DNA repair mechanisms is the cornerstone of glioblastoma treatment, alterations to DNA repair mechanisms could have a direct influence on treatment success. Our aim was to elucidate the impact of chronic hypoxia on DNA repair gene expression in a range of glioblastoma cell lines. We adopted a NanoString transcriptomic approach to examine the expression of 180 DNA repair related genes in four classical glioblastoma cell lines (U87-MG, U251-MG, D566-MG, T98G) exposed to 5 days of normoxia (21% O₂), moderate (1% O₂) or severe (0.1% O₂) hypoxia. We observed altered gene expression in several DNA repair pathways including homologous recombination repair, non-homologous end-joining and mismatch repair, with hypoxia primarily resulting in downregulation of gene expression. The extend of gene expression changes was function of the hypoxic severity. Some, but not all, of these downregulations were directly under the control of HIF activity. For example, the downregulation of *LIG4*, a key component of non-homologous end-joining, was reversed upon inhibition of the hypoxia inducible factor (HIF). In contrast, the downregulation of the mismatch repair gene, *PMS2*, was not affected by HIF inhibition. This suggests that numerous molecular mechanisms lead to hypoxia-induced reprogramming of the transcriptional landscape of DNA repair. Whilst the global impact of hypoxia on DNA repair gene expression is likely to lead to genomic instability, tumorigenesis and reduced sensitivity to anti-cancer treatment, treatment re-sensitizing might require additional approaches to a simple HIF inhibition.

Key Words

Glioblastoma, hypoxia, DNA repair, NanoString, LIG4, DNA Ligase IV, PMS2, HIF inhibition, Non-homologous end-joining, mismatch repair,

1 Introduction

2 Glioblastoma (GBM) is a highly aggressive and infiltrative grade IV astrocytoma, the most
 3 common malignant brain tumour in adults (1). Survival rates remain low partly due to the limited
 4 treatment options available. Standard protocols involve initial resection of the tumour mass,
 5 which is challenging due to the un-definable tumour border. Therefore, post-surgery
 6 radiotherapy and chemotherapy are essential for disease control. Radiotherapy is typically
 7 delivered as multiple fractions with a 60 Gy total dose (2,3). Temozolomide an alkylating agent,
 8 is the sole chemotherapeutic agent used for GBM in the UK. Using temozolomide as an
 9 adjuvant increases mean survival rate compared to radiotherapy alone (4). However, in order
 10 for temozolomide to be effective, the methylguanine methyltransferase (*MGMT*) gene must be
 11 silenced, leaving non-silenced patients with even fewer treatment options (5–8). Alternative
 12 therapies currently under investigation include PARP inhibitors, and vaccine based therapies
 13 (9–11). Despite many attempts to improve GBM outcome, survival over five years is close to
 14 zero, with numerous barriers to successful GBM treatment still remaining. One such barrier is
 15 tumour hypoxia, which can negatively influence the effectiveness of both radiotherapy and
 16 temozolomide treatment and is associated with poor patient survival for GBM and for many
 17 other solid tumours (12,13).

18 Spatial and temporal heterogeneity of oxygen availability arises due to the formation of
 19 aberrant vasculature, prone to leaks and bursts, and large diffusion distances between oxygen
 20 rich vessels and tumour cells (14,15). In the brain, healthy oxygen levels range from 5-8%, yet
 21 in GBM, cells are exposed to as little as 0.5% to 3% O₂ (16), defined as pathophysiological
 22 hypoxia. In terms of reducing anti-cancer therapy effectiveness, hypoxia can alter DNA repair
 23 mechanism through epigenetic modifications, transcription and translation alterations, and post
 24 translational modifications of DNA repair proteins (reviewed in (17)). DNA damage response is
 25 the cornerstone of GBM therapy: both radiotherapy and temozolomide target DNA, causing
 26 high levels of DNA damage which overwhelms repair mechanisms leading to the induction of
 27 apoptosis via p53 activation (18–22).

28 Hypoxia has been shown to transcriptionally downregulate homologous recombination
 29 repair (HRR) components leading to reduced HRR capacity (23–28). Also, components of
 30 nucleotide excision repair are downregulated by hypoxia even after periods of reoxygenation

(29). In addition, we previously showed that NBN and MRE11, members of a DNA double strand break recognition complex are downregulated by chronic but not acute hypoxia (30). These studies exemplify the fact that hypoxia can influence DNA repair, however, there has been little exploration of the global impact of long-term hypoxia on DNA repair gene expression in glioblastoma.

We adopted a NanoString transcriptomic approach to assess the impact of chronic hypoxia on DNA repair genes in glioblastoma cell lines. We found that hypoxia specifically affects mismatch repair (MMR), non-homologous end-joining (NHEJ) and homologous recombination repair (HRR). Additionally, we provide evidence that the hypoxia inducible factor (HIF) play a role in downregulation of some, but not all, key DNA repair genes. Downregulation of DNA repair genes by hypoxia will have significant clinical impact for cancer management and should be considered when designing new treatment methods and protocols.

Materials and Methods

Reagents: Cell culture reagents were from Gibco Life Technologies and Foetal Calf Serum from Harlan Seralab (UK). Acriflavin was purchased from Sigma Aldrich. β -Actin (Ab8226), PMS2 (Ab110638) and anti-mouse HRP (Ab6808) antibodies were from abcam. HIF-1 α (20960-1-AP) and HIF-2 α (A700-003) were from Bethyl. Anti-rabbit HRP (7074S) antibody was from Cell Signalling.

Cell Culture: U87-MG and T98G were purchased from ATCC. U251-MG were purchased from CLS. D566-MG cells were a kind gift from Prof. DD Bigner (Duke University, USA). U87-MG and T98G were cultured in modified Eagle's Medium (EMEM) with 10% FCS, 1% Sodium pyruvate. D566-MG and U251-MG were cultured using EMEM, 10% FCS, 1% sodium pyruvate and 1% non-essential amino acids. Cells were maintained at 37°C in 5% CO₂. For hypoxic experiments, cells were incubated in a Don Whitley H35 Hypoxystation for 1% O₂ or a New Brunswick Galaxy 48R incubator for 0.1% O₂. Cells were routinely tested for mycoplasma infection.

NanoString Assay: Cells were cultured in 6 cm dishes for 5 days at 21%, 1% or 0.1% O₂. RNA was extracted using High Pure RNA Extraction kit (Roche). 100 ng of total RNA was used in the NanoString assay. The expression of 180 DNA repair genes, plus 12 housekeeping genes, were assessed using the NanoString nCounter Vantage™ RNA Panel for DNA Damage and Repair (LBL-10250-03) following the manufacturer's protocol. Analysis of the NanoString data was conducted using nSolver™ Analysis Software (3.0) with nCounter® Advanced Analysis plug-in (2.0.115). Data is available at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139250>

Real Time PCR: RNA was extracted using High Pure RNA Extraction kit (Roche). Reverse transcription was conducted using SuperScript® VILO (Invitrogen) following the manufacturers guidelines. RT-PCR experiments were performed and analysed as described in (30). Primer sequences used were as follows: *LIG4* Forward:

TCCCGTTTTTGA CTCTGG Reverse: GGCAAGCTCCGTTACCTCTG, *ABL* Forward: TGGGGCATGTCCTTTCCATC Reverse: GATGTCGGCAGTGACAGTGA, *ERCC4* Forward: CTCCCTCGCCGTGTAACAAA Reverse: ACACCAAGATGCCAGTAATTAAATC, *FEN1* Forward: GTTCCTGATTGCTGTTGCGC Reverse: ATGCGAATGGTGCGGTAGAA, *MSH5* Forward: GTTTGCGAAGGTGTTGCGAA Reverse: GTCTGAGACCTCCTTGCCAC, *PARP1* Forward: GCCCTAAAGGCTCAGAACGA Reverse: CTA CTGGTCCAAGATCGCC, *UBE2T* Forward: ATGTTAGCCACAGAGCCACC Reverse: ACCTAATATTTGAGCTCGCAGGT, *WRN* Forward: TCACGCTCATTGCTGTGGAT Reverse: CAACGATTGGAACCATTGGCA, *PMS2* Forward: AGCACTGCGGTAAAGGAGTT Reverse: CAACCTGAGTTAGGTGCGCA, *CYCLOA* Forward: GCTTTGGGTCCAGGAATGG Reverse: GTTGTCCACAGTCAGCAATGGT. Cyclophilin A was used as a housekeeping gene.

Western Blotting: Western blotting was performed as described in (30). Briefly, 30-40 µg of protein were separated on 10% SDS-PAGE gels. Proteins were transferred onto nitrocellulose membrane (0.2 µm), followed by primary and secondary antibody incubation. Signal was developed using Amersham ECL Prime Western blotting Detection reagent (GE Healthcare), and images taken using a G:BOX gel imaging system (Syngene UK).

Statistical Analyses: Student T-tests were performed using GraphPad Prism 6, for comparisons of means.

Results

HRR, NHEJ and MMR are strongly regulated by hypoxia in a range of hypoxic GBM cell lines

To explore the global impact of tumour hypoxia on the expression of DNA repair genes in GBM cells, we used a NanoString assay. The NanoString nCounter gene expression system is a multiplexed assay, deemed more sensitive than RT-PCR and microarrays with less computationally heavy analysis than microarrays (31). Four classical GBM cell lines (U87-MG, U251-MG, D566-MG and T98G) were cultured in three different oxygen tensions (21%, 1% and 0.1% O₂) prior to gene expression analysis. The DNA repair genes assessed were pre-assigned to annotation groups representing cell signalling and DNA repair pathways. Directed global significance scores (DGS), which measure overall differential regulation and direction, were calculated for each cell line in 1% and 0.1% O₂ (Fig 1). Across all four cell lines, a number of pathways were downregulated, including apoptosis, mismatch repair (MMR), non-homologous end-joining (NHEJ) and homologous recombination repair (HRR) (Fig 1). Whilst previous reports show conflicted results on hypoxia-induced changes to NHEJ, with both up and down regulation of genes (17), we here observed predominantly a downregulation of this pathway. The observed downregulation of the HRR pathway in hypoxia is in line with previous findings (23–28).

Figure 1: Apoptosis, NHEJ, HRR and MMR are downregulated in multiple hypoxic GBM cell lines. (A) U87-MG, (B) U251-MG, (C) D566-MG and (D) T98G cells were incubated in 21%, 1% or 0.1% O₂ for 5 days before gene expression analysis. Directed global significance scores were calculated for each defined annotation group and cell line, in 1% and 0.1% O₂, using the NanoString nSolver Advanced Analysis Software (see methods). Scores are represented in a heat map, where red and blue represent up and downregulation respectively. Data is representative of three independent experiments.

Interestingly, increasing hypoxic severity from 1% to 0.1% O₂ drastically enhanced the regulation of each annotation group, especially in D566-MG cells (Fig 1) and also increased the number of significantly regulated genes in this cell line (Fig 2C). Beyond the specific D566-MG cells, more genes reached statistical significance at 0.1% O₂ in all cell lines, with the exception of U251-MG (Fig 2B). In U87-MG, 20 genes reached the strictest significance threshold of $p < 0.001$ in 0.1% O₂ compared to 10 genes in 1% O₂ (Fig 2A). In contrast, T98G displayed strong fold changes yet few genes reached statistical significance (Fig 2D). To validate the NanoString results and determine the robustness of the data, several gene candidates, regulated in more than one cell line, were measured by RT-PCR and showed good consistency (Fig S1). The NanoString assay therefore enabled us to successfully and robustly assess the extent of DNA repair gene expression alteration in GBM cell lines exposed to chronic hypoxia.

Figure 2: DNA repair gene regulation by hypoxia is observed across all GBM cell lines.

Gene expression data for (A) U87-MG, (B) U251-MG, (C) D566-MG and (D) T98G in 1% or 0.1% O₂ is represented as log₂ fold change with respect to 21% O₂ for each gene, plotted with log₁₀ p-value. Each point represents the average of three experimental replicates. Green filled circles signify genes that have a p-value below the $p < 0.01$ threshold (dotted line). Dashed line is at $p = 0.001$. Grey hollow circles represent non-statistically significant genes. The top 5 statistically significant genes are identified with the gene name.

Essential components of NHEJ and MMR are downregulated by hypoxia

The mismatch repair pathway removes incorrectly inserted nucleotides added during DNA replication, or removes modified bases generated by a DNA damaging agent. A sliding clamp composed of MutS α (MSH2, MSH6) and MutL α (MLH1, PMS2) actively translocates along the DNA in search of discontinuity (32–35). EXO1 is responsible for nucleotide excision, and DNA polymerases replaces excised nucleotides (36,37). The expression of 13 components of MMR were assessed in the NanoString assay (Fig 3A, B). Whilst *MSH6*, part of the MutS α complex, was unaffected by hypoxia, *MSH2* was strongly downregulated 2.3-fold in D566-MG and 2.0-fold in T98G incubated in 0.1% O₂ (Fig 3B). *PMS2*, a central component of the MutL α

complex, was also downregulated in T98G, D566-MG and U87-MG (Fig 3A, B), and was additionally a top hit in D566-MG (Fig 2C). However, there was no change to *MLH1*, the binding partner of PMS2, in line with previous studies (38). Other changes include the downregulation of *MSH5* in a number of cell lines in 1% O₂ and 0.1% O₂, with particularly strong downregulation in D566-MG (4.1-fold) at 0.1% O₂ (Fig 3B). *MSH5* is primarily involved in meiosis (39,40), therefore the impact of these hypoxia-induced changes in brain tumour cell lines is debatable. However, activation of meiotic genes has been shown to aid in the initiation and maintenance of oncogenesis (41), potentially underlying an new unknown role of the hypoxia-induced changes in *MSH5*.

Figure 3: *PMS2* and *LIG4*, essential components of MMR and NHEJ are downregulated in multiple cell lines. Differential gene expression was calculated for each gene as log₂ fold change for (A) MMR genes in 1% O₂, (B) MMR genes in 0.1% O₂, (C) NHEJ genes in 1% O₂, and (D) NHEJ in 0.1% O₂, with respect to the expression level at 21% O₂. Red shaded area denotes fold change values below the +/-0.58 log₂ fold (+/-1.5-fold) threshold of change. Blue area denotes fold change values above the designated threshold. Filled shapes represent data which is statistically significant (p<0.01), whereas hollow shapes show no statistical significance. Data are represented as the mean of three independent experiments.

NHEJ is a highly error-prone process, yet is the primary pathway for DSB repair. A DNA-PK and Ku (Ku70/Ku80) complex recognises the DSB (42,43). The ends of DNA are processed by various enzymes including Artemis, PNK, WRN and DNA polymerases (44), followed by re-joining by DNA Ligase IV complexed with XRCC4. Little consensus has been achieved as to the impact of hypoxia on NHEJ. Components of the damage recognition complex (Ku70 - *XRCC6*, Ku80 - *XRCC5*, DNA-PK - *PRKDC*) remain largely unaffected by hypoxia. However, in all the cell line tested, *LIG4* (DNA Ligase IV) was downregulated at least 1.5-fold in hypoxia (1% and 0.1% O₂), although, this was only statistically significant in U87-MG (Fig 3C, D). Interestingly, the extent of downregulation appears to strengthen with increasing hypoxia severity. In contrast, the expression level of *XRCC4*, the binding partner of

DNA Ligase IV, was not impacted by hypoxia (Fig 3C, D). Work by Meng *et al* 2005, observed similar hypoxia-induced gene expression changes for *LIG4*, with no change in *XRCC4* (24).

Overall, gene expression for components of both MMR and NHEJ were significantly impacted by hypoxia. Primarily, downregulation was observed, which could lead to reduced functionality of the repair pathways if the accessible pool of DNA repair proteins has been depleted. *PMS2* and *LIG4*, essential components of their respective repair pathways, were downregulated in at least two cell lines, therefore the mechanisms of regulation of these two genes was further examined.

Chronic and acute hypoxic exposure leads to *PMS2* and *LIG4* downregulation.

Despite the fact that hypoxic exposure in tumours is long-term, alterations to DNA repair gene expression by hypoxia are commonly explored upon acute hypoxic exposure. To determine the duration of hypoxia necessary to trigger downregulation of *PMS2* and *LIG4*, their level of expression in 1% O₂ was assessed over-time in D566-MG cells, the cell line in which the strongest regulation for these target genes was observed (Fig 4A). Both *PMS2* and *LIG4* were downregulated after only one day of hypoxic exposure and remained downregulated over the 5-day period (Fig 4A). Besides the transcriptional regulation, *PMS2* protein levels were also downregulated by chronic hypoxia in D566-MG, and U87-MG (Fig 4B), suggesting that the gene expression changes translate to the protein level. *LIG4* protein levels could not be measured, due to the lack of availability of a good quality antibody.

Figure 4: *PMS2* and *LIG4* are downregulated after acute and chronic hypoxic exposure.

(A) D566-MG cells were incubated in 1% O₂ for 1-5 days, as well as 21% O₂. After incubation, RNA was extracted and converted to cDNA for RT-PCR experiments, probing for *LIG4* and *PMS2*. Data is represented as log₂ fold change in mRNA levels with respect to level for the 21% O₂ samples. Data are the mean of at least three independent experiments, with error bars showing S.E.M. * denotes significant data where p<0.05 indicated by one-way student t-test. (B) Western blot of *PMS2* in D566-MG and U87-MG cells, incubated in 21%, 1% or 1% O₂ for 5 days. β actin was used as a loading control. Experiments were performed in triplicate, a representative blot is shown.

Previous studies demonstrated the involvement of HIF in the alteration of DNA repair gene expression. For example, downregulation of NBN, a component of HRR, arises due to the displacement of MYC by HIF at the NBN promoter (45). The HIF pathway forms a negative feedback loop with the prolyl hydroxylase domain containing protein 2 (PHD2) (46,47), resulting in a transient accumulation of HIF and lower levels after extended periods of hypoxia, typically after 12 h. However, in D566-MG and U87-MG cells, after 5 days of hypoxic exposure, HIF-1 α and HIF-2 α remained high, with similar levels at 6 h and 24 h (Fig 5A). To test the involvement of HIF in the expression levels of *LIG4* and *PMS2*, we initially aimed to use a silencing strategy. However, both D566-MG and U87-MG were highly sensitive to siRNA transfection performed to knockdown HIF (data not shown), therefore a pharmacological approach was adopted. Acriflavin can inhibit HIF-1 and HIF-2 through binding to the PAS-B subdomain in the α subunit, preventing dimerisation of the α and β subunits, and reducing HIFs transcriptional activity (48). Treatment with acriflavin was sufficient to reduce hypoxia-induced *GLUT1* expression, a typical HIF target gene (Fig S2A). In both D566-MG and U87-MG cell lines, acriflavin abrogated hypoxia-induced *LIG4* mRNA regulation (Fig 5B). In contrast, the level of *PMS2* was not altered by acriflavin treatment (Fig S2B), suggesting different mechanisms of regulation for both genes, and that HIF is not the only player in hypoxia-induced regulation of DNA repair genes.

Figure 5: HIF inhibition by Acriflavin restored *LIG4* downregulation. (A) HIF-1 α and HIF-2 α are upregulated in chronic hypoxia. U87-MG and D566-MG cells were incubated in 1% O₂ and 21% O₂ for 0-120 h. Protein was extracted and the levels of HIF-1 α and HIF-2 α determined by western blotting in two independent experiments. A representative blot is shown. (B) D566-MG and U87-MG cells were incubated in 21% and 1% O₂ for 24 h with and without 5 μ M Acriflavin. *LIG4* mRNA levels were measured by RT-PCR. Data are represented as log₂ fold change in mRNA levels with respect to 21% O₂ samples. Data are the mean of at least three independent experiments, with error bars showing S.E.M. * denotes significant data where p<0.05 indicated by one-way student t-test.

Discussion

Tumour hypoxia plays an essential role in tumour progression, metastasis and drug resistance, leading to poor patient outcome particularly for GBM patients. Hypoxia has been shown to impact numerous signalling pathways including the cell cycle, metabolism and apoptosis, yet additionally hypoxia can have a significant impact on DNA repair mechanisms. We have shown here that several key DNA repair pathways were downregulated by hypoxia, including MMR and NHEJ, both essential pathways for the repair of modified/mismatch bases and double strand breaks respectively. Further analysis determined that *PMS2* (MMR) and *LIG4* (NHEJ), essential components of their respective pathways, were downregulated across multiple cell lines after chronic and acute hypoxic exposure, providing potential targets for re-sensitisation of hypoxic tumour cells to DNA damaging therapies.

Mismatch repair an essential repair pathway for TMZ efficacy

We observed hypoxia-induced downregulation of *PMS2* (Figure 3A, B), a vital component of MMR, involved in the search for discontinuity in DNA. MMR is required for repair of mismatched bases resulting from replication errors or DNA damaging agents. Defects in any of the critical MMR repair proteins (*PMS2*, *MLH1*, *MSH2*, *MSH6*), can lead to hypermutation and microsatellite instability, due to the increased number of point mutations (49). These point mutations drive tumorigenesis and cancer progression, which will directly contribute to poor patient outcome. In multicellular brain tumour spheroids, downregulation of *PMS2* and *MLH1* promoted the initiation of tumour cell formation and growth (50). In addition, in 1996, the link between MMR and cisplatin resistance was established, when cisplatin-resistant human ovarian adenocarcinoma cells were found to have reduced *MLH1* protein (51). In the same year, the downregulation of both *MLH1* and *MLH2* was found to induce cisplatin and carboplatin resistance (52), although this was only a low-level resistance. We see little change in the gene expression of *MLH1* and *MLH2*, however, previously, we have reported that indeed, hypoxia causes low level resistance to cisplatin in GBM cells (30), which could be due to *PMS2* downregulation. More importantly for GBM, MMR is essential for TMZ-induced apoptosis (53). Loss of *MSH6* has been associated with increased tumour progression during temozolomide treatment in GBM (54), and alterations of *MSH2* expression

can predict patient response to temozolomide therapy, with reduced expression correlating with decreased overall patient survival (55). Downregulation of *PMS2* in hypoxia could have a significant clinical impact for GBM by contributing to increased mutation rate driving tumorigenesis and reduced sensitivity to temozolomide.

DNA Ligase IV is crucial for NHEJ fidelity

NHEJ, a highly error prone repair process, is essential for effective induction of apoptosis by temozolomide treatment (56). Among the the key components of NHEJ, we observed a significant hypoxia-induced downregulation of *LIG4* in multiple GBM cell lines, in line with previous observations (24). DNA Ligase IV is essential for re-joining broken DNA ends, yet is also required to prevent degradation of the ends of DNA, thus promoting accurate re-joining (57). Cell lines with hypermorphic mutations in *LIG4*, resulting in residual DNA Ligase IV function, are able to perform end-joining yet with reduced fidelity. In mice, loss of a single allele of *LIG4* results in the formation of soft tissue sarcomas, as a result of increased genomic instability (58). Therefore, downregulation of *LIG4* may reduce the effectiveness of NHEJ, thereby promoting genomic instability and further fuel tumorigenesis. However, in contrast, *LIG4* deficient cell lines have been shown to be more sensitive to ionizing radiation (59). Additionally, work by Kondo *et al* found that *LIG4* deficient cells were also more sensitive to temozolomide and Nimustine (ACNU), and siRNA of *LIG4* enhanced cell lethality of both chemotherapeutics (56,60). Although an increased genetic instability potentially arising due to *LIG4* downregulation may drive development and progression of GBM, the potential positive impact of increased temozolomide sensitivity may outweigh this negative implication. This highlights the double-edged sword of hypoxia, where both pro- and anti-cancer adaptations arise, which can be complex and difficult to untangle. Discovery of targeted therapies, which can exploit the anti-cancer components of tumour hypoxia would be advantageous, yet for this to occur further understanding of the molecular mechanism of hypoxia-induced changes needs to be gained.

The role of HIF in hypoxia-induced DNA repair gene regulation

Long term hypoxia-induced changes in DNA repair gene expression can be orchestrated by a range of mechanisms, including epigenetic modifications. For example, alterations to histone methylation and acetylation at the promoters of *BRCA1* and *RAD51* leads to reduced gene expression (61). However, short-term transient changes to DNA repair gene expression are more commonly studied, with mechanisms both dependent and independent of HIF being described. Using an inhibitor of HIF, we showed that HIF is involved in the downregulation of *LIG4* but not *PMS2* in hypoxic GBM cells (Figure 5B). HIF can directly modulate the transcription of genes through binding at the hypoxic response elements within promoters of DNA repair genes. For example, in the *MLH1* promoter, hypoxia response elements have been identified (62) suggesting direct HIF regulation, yet a mechanism of *MLH1* downregulation independent of HIF have also been discovered (38,62,63).

On the other hand, other genes are altered in a HIF-independent way, such as for example, via the E2F transcription factor binding in hypoxia. Indeed, in normoxia, the expression of *BRCA1* is mediated through the binding of the activating factor E2F1 as well as the E2F4/p130 suppressor. However, under hypoxic conditions, p130 binding to E2F4 is enhanced, due to alterations to p130 post-translational modifications. This results in an increase in E2F4/p130 transcriptional suppressor binding at the *BRAC1* promoter, reducing the rate of transcription (26). Regulation of *RAD51* and *FANCD2* is thought to also occur by an E2F related mechanism (23,64). The regulation of *PMS2* may be through a similar mechanism.

Conclusions

We have shown that chronic hypoxia results in the downregulation of multiple DNA repair pathways in GBM including essential components of MMR and NHEJ pathways. These alterations will likely not only impact chemotherapeutic treatment efficiency but also enhance the tumour genomic instability, hence further fuelling its development. The development of HIF inhibitors for cancer treatment is currently a popular area of research (reviewed in (65)), and will undoubtedly be of great benefit for reducing the undesirable pro-tumorigenic impact of hypoxia. However, HIF is not the sole regulator of the hypoxia-induced reprogramming of

329 the transcriptional landscape of DNA repair, as we have shown here with *PMS2* regulation.
330 Whether HIF inhibition could be sufficient to re-sensitise hypoxic brain tumour cells to radio-
331 and chemotherapy will require further investigation.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the Alder Hey Oncology Fund.

Acknowledgements

We thank the Centre for Genomics at UoL for training and advice for the NanoString experiments.

Author contribution

Sophie Cowman performed all the experiments, analysis, interpretation, statistical analysis, prepared figures and drafted the manuscript. Barry Pizer provided clinical input, co-supervised the project and contributed to acquiring funding for the project. Violaine See conceived and co-ordinated the study and edited the manuscript. All authors reviewed a final draft of the manuscript and gave approval.

References

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. *Neuro Oncol.* 2012;14(SUPPL_5):v1–88.
2. Omuro A, DeAngelis LM. Glioblastoma and Other Malignant Gliomas. *Jama* [Internet]. 2013;310(17):1842. Available from: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.280319>
3. Chang CH, Horton J, Schoenfeld D, Salazar O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. *Cancer.* 1983;52(6):997–1007.
4. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. *J Clin Oncol.* 2005;23(10):2372–7.
5. Esteller M, Garcia-Foncillas J, Andion E. Inactivation of The DNA Repair Gene MGMT And The Clinical Response of Gliomas to Alkylating Agents. *N Engl J Med.* 2000;343(19):4–8.
6. Hegi., Marie-france, Tribolet N De, Weller M, Kros JM, Hainfellner JA, et al. Gene Silencing and Benefit from Temozolomide in Glioblastoma. *N Engl J Med.*

2005;352(10):997–1003.

7. Glassner BJ, Weeda G, Allan JM, Broekhof JLM, Carls NHE, Donker I, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. *Mutagenesis*. 1999;14(3):339–47.
8. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. *Br J Cancer* [Internet]. 1999 Nov;81(6):1022–30. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2362937&tool=pmcentrez&rendertype=abstract>
9. Cheng CL, Johnson SP, Keir ST, Quinn J a, Ali-Osman F, Szabo C, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. *Mol Cancer Ther*. 2005;4(9):1364–8.
10. Zhang Z, Tang L, Zhan R, Tong Y, Yao H, Du L. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA. *J Zhejiang Univ Sci*. 2004;5(10):1298–303.
11. Liao LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. *J Transl Med* [Internet]. 2018;16(142):1–9. Available from: <https://doi.org/10.1186/s12967-018-1507-6>
12. Ge X, Pan MH, Wang L, Li W, Jiang C, He J, et al. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis. *Cell Death Dis* [Internet]. 2018;9(11). Available from: <http://dx.doi.org/10.1038/s41419-018-1176-7>
13. Marampon F, Gravina GL, Zani BM, Popov VM, Fratticci A, Cerasani M, et al. Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF- 1 α functional interplay. *Int J Oncol*. 2014;45(6):2121–31.
14. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. *Oncologist* [Internet]. 2004 [cited 2014 Dec 8];9(5):4–9. Available from: https://theoncologist.alphamedpress.org/content/9/suppl_5/4.full
15. Vaupel P, Rallinoâ F, Okunieff P. Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment Human Tumors: A Review. *Cancer Res*. 1989;49(23):6449–65.
16. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO₂ distribution and bioreductive enzymes in human malignant brain tumors. *Int J Radiat Oncol* [Internet]. 1994;29(3):427–31. Available from: [http://www.sciencedirect.com/science/article/pii/0360301694904324#%5Cnhttp://www.sciencedirect.com/science/article/pii/0360301694904324/pdf?md5=de4584ca25998c548ecbae17](http://www.sciencedirect.com/science/article/pii/0360301694904324#%5Cnhttp://www.sciencedirect.com/science/article/pii/0360301694904324#%5Cnhttp://www.sciencedirect.com/science/article/pii/0360301694904324/pdf?md5=de4584ca25998c548ecbae17)

48de2828&pid=1-s2.

17. Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. *DNA Repair (Amst)* [Internet]. 2015;32:180–9. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1568786415001226>
18. Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, et al. Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage. *Science* (80-). 1998;281(5383):1674–7.
19. Saito SNI, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, et al. ATM mediates phosphorylation at multiple p53 sites, including Ser46, in response to ionizing radiation. *J Biol Chem*. 2002;277(15):12491–4.
20. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science* (80-). 1998;281(5383):1677–9.
21. Epstein ACR, Gleadle JM, McNeill LA, Hewitson KS, Rourke JO, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell*. 2001;107:43–54.
22. Turenne GA, Paul P, Laflair L, Price BD. Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53. *Oncogene*. 2001;20(37):5100–10.
23. Bindra RS, Glazer PM. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. *Oncogene*. 2007;26(14):2048–57.
24. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. *Radiother Oncol*. 2005;76(2):168–76.
25. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. *Cancer Res*. 2008;68(2):605–14.
26. Bindra RS, Gibson SL, Meng A, Westermarck U, Jasin M, Pierce AJ, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. *Cancer Res*. 2005;65(24):11597–604.
27. Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, et al. Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. *Mol Cell Biol*. 2004;24(19):8504–18.
28. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. *Cancer Metastasis Rev*. 2007;26(2):249–60.

29. Dudás J, Schartinger VH, Romani A, Schweigl G, Kordsmeyer K, Marta PI, et al. Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. *Tumor Biol.* 2014;35(8):7807–19.
30. Cowman S, Fan YN, Pizer B, Sée V. Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells. *BMC Cancer.* 2019;19(1):1–16.
31. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat Biotechnol.* 2008;26(3):317–25.
32. Gradia S, Acharya S, Fishel R. The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. *Cell.* 1997;91(7):995–1005.
33. Iaccarino I, Marra G, Dufner P, Jiricny J. Mutation in the magnesium binding site of hMSH6 disables the hMutSα sliding clamp from translocating along DNA. *J Biol Chem.* 2000;275(3):2080–6.
34. Blackwell LJ, Martik D, Bjornson KP, Bjornson ES, Modrich P. Nucleotide-promoted release of hMutSα from heteroduplex DNA is consistent with an ATP-dependent translocation mechanism. *J Biol Chem.* 1999;273(48):32055–62.
35. Gradia S, Subramanian D, Wilson T, Acharya S, Makhov A, Griffith J, et al. hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. *Mol Cell.* 1999;3(2):255–61.
36. Zhang Y, Yuan F, Presnell SR, Tian K, Gao Y, Tomkinson AE, et al. Reconstitution of 5'-directed human mismatch repair in a purified system. *Cell.* 2005;122(5):693–705.
37. Longley MJ, Pierce AJ, Modrich P. DNA polymerase δ is required for human mismatch repair in vitro. *J Biol Chem.* 1997;272(16):10917–21.
38. Koshiji M, To KKW, Hammer S, Kumamoto K, Harris AL, Modrich P, et al. HIF-1 α induces genetic instability by transcriptionally downregulating MutS α expression. *Mol Cell.* 2005;17(6):793–803.
39. Bocker T, Barusevicius A, Snowden T, Rasio D, Guerrette S, Robbins D, et al. hMSH5: A human MutS homologue that forms a novel heterodimer with hMSH4 and is expressed during spermatogenesis. *Cancer Res.* 1999;59(4):816–22.
40. Snowden T, Acharya S, Butz C, Berardini M, Fishel R. hMSH4-hMSH5 recognizes holliday junctions and forms a meiosis-specific sliding clamp that embraces homologous chromosomes. *Mol Cell.* 2004;15(3):437–51.
41. McFarlane RJ, Wakeman JA. Meiosis-like functions in oncogenesis: A new view of

- cancer. *Cancer Res.* 2017;77(21):5712–6.
42. Gottlieb TM, Jackson P. The DNA-Dependent Protein Kinase: Requirement for DNA ends and Association with Ku Antigen. *Cell.* 1993;72:131–42.
 43. Kurimasa A, Kumano S, Boubnov N V, Story MD, Tung CS, Peterson SR, et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. *Mol Cell Biol* [Internet]. 1999;19(5):3877–84. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=84245&tool=pmcentrez&rendertype=abstract>
 44. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. *Biochem J* [Internet]. 2009;417(3):639–50. Available from: <http://biochemj.org/lookup/doi/10.1042/BJ20080413>
 45. To KK-W, Sedelnikova O a, Samons M, Bonner WM, Huang LE. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. *EMBO J* [Internet]. 2006;25(20):4784–94. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1618093&tool=pmcentrez&rendertype=abstract>
 46. Stiehl DP, Wirthner R, Köditz J, Spielmann P, Camenisch G, Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels: Evidence for an autoregulatory oxygen-sensing system. *J Biol Chem.* 2006;281(33):23482–91.
 47. Bagnall J, Leedale J, Taylor SE, Spiller DG, White MRH, Sharkey KJ, et al. Tight control of hypoxia-inducible factor- α transient dynamics is essential for cell survival in hypoxia. *J Biol Chem.* 2014;289(9):5549–64.
 48. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. *Proc Natl Acad Sci* [Internet]. 2009;106(42):17910–5. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.0909353106>
 49. Kim N, Bozek G, Lo JC, Storb U. Different mismatch repair deficiencies all have the same effects on somatic hypermutation: intact primary mechanism accompanied by secondary modifications. *J Exp Med* [Internet]. 1999;190(1):21–30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10429667>
 50. Collins SL, Hervé R, Keevil CW, Blaydes JP, Webb JS. Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids. *PLoS One.* 2011;6(12):1–8.
 51. Aebi S, Kurdi-haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA Mismatch Repair in Acquired Resistance to Cisplatin Loss of DNA Mismatch Repair in Acquired Resistance to Cisplatin. *Cancer Res.* 1996;2(619):3087–90.

52. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. *Clin Cancer Res.* 1998;4:1–6.
53. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. *Mol Pharmacol.* 1998;54(2):334–41.
54. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. *Clin Cancer Res.* 2007;13(7):2038–45.
55. McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, et al. Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. *Cancer Res.* 2015;75(15):3127–38.
56. Kondo N, Takahashi A, Mori E, Ohnishi K, McKinnon PJ, Sakaki T, et al. DNA ligase IV as a new molecular target for temozolomide. *Biochem Biophys Res Commun* [Internet]. 2009;387(4):656–60. Available from: <http://dx.doi.org/10.1016/j.bbrc.2009.07.045>
57. Smith J, Riballo E, Kysela B, Baldeyron C, Manolis K, Masson C, et al. Impact of DNA ligase IV on the fidelity of end joining in human cells. *Nucleic Acids Res.* 2003;31(8):2157–67.
58. Sharpless NE, Ferguson DO, O'hagan RC, Castrillon DH, Lee C, Farazi PA, et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. *Mol Cell.* 2001;8(6):1187–96.
59. Adachi N, Ishino T, Ishii Y, Takeda S, Koyama H. DNA ligase IV-deficient cells are more resistant to ionizing radiation in the absence of Ku70: Implications for DNA double-strand break repair. *Proc Natl Acad Sci.* 2002;98(21):12109–13.
60. Kondo N, Takahashi A, Mori E, Noda T, Su X, Ohnishi K, et al. DNA ligase IV is a potential molecular target in ACNU sensitivity. *Cancer Sci.* 2010;101(8):1881–5.
61. Lu Y, Chu A, Turker MS, Glazer PM. Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter. *Mol Cell Biol* [Internet]. 2011;31(16):3339–50. Available from: <http://mcb.asm.org/cgi/doi/10.1128/MCB.01121-10>
62. Mihaylova VT, Bindra RS, Yuan J, Campisi D, Narayanan L, Jensen R, et al. Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells. *Mol Cell Biol.* 2003;23(9):3265–73.
63. Rodríguez-Jiménez FJ, Moreno-Manzano V, Lucas-Dominguez R, Sánchez-Puelles J-M. Hypoxia Causes Downregulation of Mismatch Repair System and Genomic Instability in Stem Cells. *Stem Cells* [Internet]. 2008;26(8):2052–62. Available from:

<http://doi.wiley.com/10.1634/stemcells.2007-1016>

64. Scanlon SE, Glazer PM. Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins. *Mol Cancer Res.* 2014;12(7):1016–28.
65. Fallah J, Rini BI. HIF Inhibitors: Status of Current Clinical Development. *Curr Oncol Rep [Internet].* 2019 Jan;21(1):6. Available from: <https://doi.org/10.1007/s11912-019-0752-z>

Figure S1: NanoString Validation by RT-PCR. Seven genes were selected from the NanoString panel for validation by RT-PCR. cDNA samples for (A) U87-MG, (B) U251-MG and (C) D566-MG was utilised in RT-PCR experiments to assess the expression levels of selected genes. Data are expressed as log₂ fold change with respect to expression at 21% O₂. Data from NanoString is included for direct comparison. RT-PCR data is represented as the mean of three independent experiments.

Figure S2: Impact of Acriflavin on *GLUT1* and *PMS2* gene expression. (A) D566-MG cells were incubated in 0.1% O₂ and treated with 0-10 µM Acriflavin for 24 h. Control cells remained in 21% O₂. RT-PCR was performed to assess *GLUT1* expression levels. Data represent the fold change in *GLUT1* expression relative to 21% O₂. Data are from a single experiment. (B) HIF inhibition does not restore *PMS2* mRNA levels in hypoxia. D566-MG and U87-MG cells were incubated in 21% and 1% O₂ for 24 h with and without 5 µM Acriflavin, the plots show the log₂ fold change in mRNA levels with respect to levels for the 21% O₂ samples. Data are the mean of at least two independent experiment.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5